Related Posts

• 
  The Choice of Outcome Parameters and Need for Distinct Assessment Tools with Regard to the Different Disease Stages in Alzheimer’s Disease (Video)
• 
  A Path to Accelerating Treatments for Neurodegenerative Diseases
• 
  CTAD, Harmonizing Regulatory Requirements to Benefit Alzheimer’s Disease Patients: Lessons learned from Critical Path Institute
• 
  RASAD – AD Biomarkers: Regulatory Science Path
• 
  CALBIO2012 – Role of Patient Advocacy Groups in Accelerating Drug Development